Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Nov;37(11):2318–2322. doi: 10.1128/aac.37.11.2318

Uptake of azithromycin by human monocytes and enhanced intracellular antibacterial activity against Staphylococcus aureus.

A P Meyer 1, C Bril-Bazuin 1, H Mattie 1, P J van den Broek 1
PMCID: PMC192385  PMID: 8285612

Abstract

The uptake of azithromycin by human monocytes and the intracellular antibacterial activity of azithromycin against Staphylococcus aureus were investigated. With an extracellular pH of 6.9, the maximum intracellular concentration of azithromycin in monocytes was about six times the extracellular concentration. The half-life for diffusion was 44 min. The results support the view that no active transport is involved in the intracellular accumulation of azithromycin. In cell-free medium, the maximum effect of azithromycin on S. aureus was bacteriostasis, which was achieved at a concentration of 5 mg/liter. In contrast, concentrations greater than 1.5 mg of azithromycin per liter were bactericidal for S. aureus ingested by monocytes. The difference in maximum growth inhibition on S. aureus for the two conditions was 0.1.68 h-1 (95% confidence interval, 0.128 to 0.208). The concentration of the drug that achieved 50% of the maximum effect was 0.434 mg/liter for both conditions. The enhancement of the effect on S. aureus ingested by monocytes suggests that the intracellular environment in human monocytes favors the antibacterial action of azithromycin. Enhancement of the antibacterial activity of azithromycin was not observed with granulocytes.

Full text

PDF
2318

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Gladue R. P., Bright G. M., Isaacson R. E., Newborg M. F. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother. 1989 Mar;33(3):277–282. doi: 10.1128/aac.33.3.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Laufen H., Wildfeuer A., Lach P. Mechanism of azithromycin uptake in human polymorphonuclear leucocytes. Arzneimittelforschung. 1990 Jun;40(6):686–689. [PubMed] [Google Scholar]
  3. Leijh P. C., van den Barselaar M. T., van Zwet T. L., Daha M. R., van Furth R. Requirement of extracellular complement and immunoglobulin for intracellular killing of micro-organisms by human monocytes. J Clin Invest. 1979 Apr;63(4):772–784. doi: 10.1172/JCI109362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Mattie H., Goslings W. R., Noach E. L. Cloxacillin and nafcillin: serum binding and its relationship to antibacterial effect in mice. J Infect Dis. 1973 Aug;128(2):170–177. doi: 10.1093/infdis/128.2.170. [DOI] [PubMed] [Google Scholar]
  5. Milatovic D. Intraphagocytic activity of erythromycin, roxithromycin and azithromycin. Eur J Clin Microbiol Infect Dis. 1990 Jan;9(1):33–35. doi: 10.1007/BF01969530. [DOI] [PubMed] [Google Scholar]
  6. Nibbering P. H., Zomerdijk T. P., Corsèl-Van Tilburg A. J., Van Furth R. Mean cell volume of human blood leucocytes and resident and activated murine macrophages. J Immunol Methods. 1990 May 8;129(1):143–145. doi: 10.1016/0022-1759(90)90432-u. [DOI] [PubMed] [Google Scholar]
  7. Paulsen P., Simon C., Peters O., Hedderich J., Heim P. Influence of azithromycin and other macrolides on the intracellular killing of Staphylococcus aureus by human polymorphonuclear leucocytes of healthy donors and a patient with Chédiak-Higashi syndrome. Chemotherapy. 1992;38(3):185–190. doi: 10.1159/000238961. [DOI] [PubMed] [Google Scholar]
  8. Raghoebar M., Lindeyer E., Van den Berg W. B., Van Ginneken C. A. On the mechanisms of association of the macrolide antibiotic erythromycin with isolated human polymorphonuclear leucocytes. Biochem Pharmacol. 1988 Sep 1;37(17):3221–3227. doi: 10.1016/0006-2952(88)90631-4. [DOI] [PubMed] [Google Scholar]
  9. Sabath L. D., Gerstein D. A., Loder P. B., Finland M. Excretion of erythromycin and its enhanced activity in urine against gram-negative bacilli with alkalinization. J Lab Clin Med. 1968 Dec;72(6):916–923. [PubMed] [Google Scholar]
  10. Whiting B., Kelman A. W. The modelling of drug response. Clin Sci (Lond) 1980 Nov;59(5):311–315. doi: 10.1042/cs0590311. [DOI] [PubMed] [Google Scholar]
  11. van den Broek P. J., Buys L. F., Aleman B. M. The antibacterial activity of benzylpenicillin against Staphylococcus aureus ingested by granulocytes. J Antimicrob Chemother. 1990 Jun;25(6):931–940. doi: 10.1093/jac/25.6.931. [DOI] [PubMed] [Google Scholar]
  12. van den Broek P. J., Buys L. F., van Furth R. Adherence of lysostaphin to and penetration into human monocytes. Scand J Immunol. 1985 Feb;21(2):189–193. doi: 10.1111/j.1365-3083.1985.tb01419.x. [DOI] [PubMed] [Google Scholar]
  13. van den Broek P. J., Dehue F. A., Leijh P. C., van den Barselaar M. T., van Furth R. The use of lysostaphin in in vitro assays of phagocyte function: adherence to and penetration into granulocytes. Scand J Immunol. 1981 May;15(5):467–473. doi: 10.1111/j.1365-3083.1982.tb00672.x. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES